Steris (Steris) Change In Working Capital : $-141 Mil (TTM As of Dec. 2023)

View and export this data going back to 1992. Start your Free Trial

What is Steris Change In Working Capital?

Steris's change in working capital for the quarter that ended in Dec. 2023 was $-16 Mil.

Steris's change in working capital for the fiscal year that ended in Mar. 2023 was $-250 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Steris Change In Working Capital Historical Data

The historical data trend for Steris's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Steris Change In Working Capital Chart

Steris Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Change In Working Capital

Get a 7-Day Free Trial

10.34

-49.81

19.01

-149.28

-250.02

Steris Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Working Capital	Get a 7-Day Free Trial															-60.60	7.50	6.19	-139.27	-15.71

Steris Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-141 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Steris Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Steris's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Steris (Steris) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Steris PLC (NYSE:STE) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

S1TE34:Brazil

Address

5960 Heisley Road, Mentor, OH, USA, 44060

Website

https://www.steris-ir.com

Steris is an Ireland-domiciled medical device company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its 2015 inversion to Ireland, the firm continues to derive roughly 70% of revenue from its U.S. operations, 10% from the United Kingdom, and the remaining 20% from other international regions.

Executives

Richard C Breeden	director	100 SOUTH WACKER, SUITE 1800, CHICAGO IL 60606
Cynthia L Feldmann	director	17 WINTHROP ROAD, WAYLAND MA 01778
Jacqueline B Kosecoff	director	5960 HEISLEY ROAD, MENTOR OH 44060
Mohsen Sohi	director	C/O STERIS CORPORATION, 5960 HEISLEY ROAD, MENTOR OH 44060
Esther M. Alegria	director	2642 MICHELLE DRIVE, SUITE 200, TUSTIN CA 92780
Cary L Majors	officer: VP, N America Com Operations	5960 HEISLEY ROAD, MENTOR OH 44060
John Adam Zangerle	director, officer: Sr. VP, Gen Counsel, and Sec.	5960 HEISLEY ROAD, MENTOR OH 44060
Michael J Tokich	director, officer: Sr. Vice Pres., CFO	C/O STERIS CORP, 5960 HEISLEY RD, MENTOR OH 44060
Karen L Burton	officer: VP, Controller & CAO	5960 HEISLEY ROAD, MENTOR OH 44060
Renato Tamaro	officer: V.P. & Corporate Treasurer	5960 HEISLEY ROAD, MENTOR OH 44060
Andrew Xilas	officer: SVP and GM, Dental	5960 HEISLEY ROAD, MENTOR OH 44060
Paul Edward Martin	director	C/O UNISYS CORPORATION, 801 LAKEVIEW DRIVE, SUITE 100, BLUE BELL PA 19422
Julia Madsen	officer: Senior VP, Life Sciences	5960 HEISLEY ROAD, MENTOR OH 44060
David B Lewis	director
Rosebrough Walter M Jr	officer: President & CEO	5960 HEISLEY ROAD, MENTOR OH 44060